Search

Zealand Pharma A-S

Geschlossen

225.5 -1.31

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

224.4

Max

226.8

Schlüsselkennzahlen

By Trading Economics

Einkommen

4.3B

3.9B

Verkäufe

4.5B

4.5B

KGV

Branchendurchschnitt

6.077

48.735

EPS

55.34

Gewinnspanne

87.219

Angestellte

578

EBITDA

4.2B

3.9B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+25.15% upside

Dividenden

By Acuity

Nächstes Ergebnis

12. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-6.7B

16B

Vorheriger Eröffnungskurs

226.81

Vorheriger Schlusskurs

225.5

Zealand Pharma A-S Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Okt. 2026, 23:51 UTC

RBA Kent Speech on October 18 to Address Interest Rates Amid Global Economic Uncertainty and Inflation Concerns.

17. Okt. 2026, 23:41 UTC

China's Loan Prime Rate Expected to Remain Steady at 3.5% Amid Economic Uncertainties and Weak Credit Growth

17. Okt. 2026, 23:41 UTC

China's Loan Prime Rate expected to remain stable at 3% amid economic uncertainties and global inflation concerns, with market focus on potential impacts from geopolitical tensions.

17. Okt. 2026, 23:31 UTC

China's House Price Index YoY release on October 19, 2026, expected to show continued pressure amid economic challenges and rising mortgage rates.

17. Okt. 2026, 23:11 UTC

Ethereum is trading lower amid broader market pressures from a selloff in technology stocks and rising fears of increased interest rates following inflation data.

17. Okt. 2026, 23:01 UTC

US Building Permits Forecasted at 1.4 Million Amid Mixed Housing Market Sentiment and High Mortgage Rates

17. Okt. 2026, 23:01 UTC

Cautious Market Awaits U.S. Housing Starts Data Amid Economic Uncertainties on October 20, 2026

17. Okt. 2026, 23:01 UTC

U.S. Building Permits Report Set for Release Amid Cautious Market Sentiment and Rising Mortgage Rates

17. Okt. 2026, 23:01 UTC

U.S. Housing Starts Data Release on October 20 Expected to Show Cautious Forecast of 1.3 Million Amid Rising Mortgage Rates and Economic Uncertainty

17. Okt. 2026, 22:51 UTC

Brazil's Central Bank to Provide Key Interest Rate Insights on October 19 Amid Global Economic Caution.

17. Okt. 2026, 22:51 UTC

Japan's Core Inflation Rate Expected to Rise to 2.1% Amid Positive Market Sentiment and BOJ Governor Ueda's Remarks on Monetary Policy Adjustments

17. Okt. 2026, 22:51 UTC

Japan's Inflation Rate Release on October 22 Expected Amidst Market Optimism and Geopolitical Concerns.

17. Okt. 2026, 22:41 UTC

Canada's Inflation Rate YoY for September 2026 set to release on October 19, with market focus on persistent high prices and potential impacts on monetary policy.

17. Okt. 2026, 22:41 UTC

Canada's Core Inflation Rate Release on October 19, 2026, Sparks Cautious Optimism Amid Mixed Economic Sentiment and Rising Interest Rate Concerns.

17. Okt. 2026, 22:41 UTC

Canada's Inflation Rate Set to Rise 0.2% in September Amidst Market Volatility and Global Price Pressures

17. Okt. 2026, 22:41 UTC

Mortgage rates hit three-year high at 7.4%, raising concerns over housing affordability and buyer hesitance ahead of upcoming MBA report.

17. Okt. 2026, 22:31 UTC

Japan's Upcoming Exports YoY Data Release on October 20, 2026, Sparks Cautious Optimism Amid Recovery in Asian Markets and Technology Sector.

17. Okt. 2026, 22:31 UTC

UK Consumer Confidence Set to Improve Slightly in October Amid Mixed Economic Signals and Inflation Concerns

17. Okt. 2026, 22:31 UTC

Japan's trade balance forecasted to show a -250 billion yen deficit amid rising import costs and currency weakness, as markets cautiously rebound ahead of October 20 report.

17. Okt. 2026, 22:11 UTC

Turkey's TCMB Expected to Maintain Interest Rate at 37% Amid Inflation and Geopolitical Tensions on October 22, 2026.

17. Okt. 2026, 22:01 UTC

News

Ethereum is trading lower, continuing a downward trend amid broader market weakness in technology stocks and concerns over AI financing issues.

17. Okt. 2026, 22:01 UTC

Correlated Moves

Cardano is trading lower, continuing its downward trend alongside Ethereum, amid broader market weakness and concerns over AI financing issues.

17. Okt. 2026, 22:01 UTC

News

Ethereum is trading lower, continuing a downward trend amid broader market weakness in technology stocks due to concerns over AI financing issues.

17. Okt. 2026, 22:01 UTC

Correlated Moves

XRP is declining, continuing a downward trend since Friday, amid broader cryptocurrency market losses linked to concerns over AI financing and inflation data.

17. Okt. 2026, 22:01 UTC

Correlated Moves

Avalanche is declining amid broader market weakness, influenced by concerns over AI financing issues, while Ethereum also trades lower.

17. Okt. 2026, 21:21 UTC

Optimism Grows Ahead of Australia's S&P Global Manufacturing PMI Flash Release Amid Strong Market Performance and Positive Economic Sentiment

17. Okt. 2026, 21:21 UTC

Australia's S&P Global Services PMI Flash on October 22 expected to reflect positive business activity amid rising stock market optimism and supportive global economic sentiment.

17. Okt. 2026, 21:11 UTC

Spanish Consumer Confidence Index Set for Release on October 19, Amidst Mixed Economic Signals and Rising Inflation Concerns.

17. Okt. 2026, 21:11 UTC

CBI Business Optimism Index for Q4 2026 Set to Reflect Increased UK Manufacturing Sentiment Amid Positive Industrial Trends and Investor Confidence.

17. Okt. 2026, 21:11 UTC

UK CBI Industrial Trends Orders Forecast at -20 for October 2026, Indicating Gradual Recovery Amid Improved Investor Sentiment.

Peer-Vergleich

Kursveränderung

Zealand Pharma A-S Prognose

Kursziel

By TipRanks

25.15% Vorteil

12-Monats-Prognose

Durchschnitt 270.582 DKK  25.15%

Hoch 270.568 DKK

Tief 270.568 DKK

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zealand Pharma A-S – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

1 ratings

0

Buy

1

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Zealand Pharma A-S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
help-icon Live chat